Market News & Trends
Ovid Therapeutics Dosed Healthy Volunteers With OV329 in Phase 1 Trial
Ovid Therapeutics Inc. recently dosed healthy volunteers with OV329 in late December 2022, as part of a Phase 1 study. The company is conducting the…
IMUNON Enters Collaborative Research Agreement With The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
IMUNON, Inc. and The Wistar Institute recently announced the signing of a first collaborative research agreement to research and develop new vaccine formulations utilizing IMUNON’s PLACCINE modality for the….
Clearmind Medicine Shows Efficacy of Psychedelic-Derived Obesity Treatment in Preclinical Trial
Clearmind Medicine Inc. recently announced positive preclinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome. The study, conducted at…
Purple Biotech & Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
Purple Biotech Ltd. recently announced a research collaboration with Mor Research Applications that provides Purple Biotech first access to early stage oncology product candidates owned by….
HRA Pharma Rare Diseases Registers the first Cushing’s Syndrome Treatment in Colombia
HRA Pharma Rare Diseases, an affiliate of HRA Pharma, a Perrigo Company, recently announced the registration of the first ever treatment for Cushing’s syndrome, Metopirone,…
Biognosys & Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma & Biomarker Customers
New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics….
Oncorus Announces Research Collaboration With Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise….
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
Verrica Pharmaceuticals Inc. recently announced the successful completion of the technology transfer of bulk solution manufacturing to Piramal Pharma Solutions. The technology transfer includes the…
Certara Acquires Artificial Intelligence Company That Delivers Predictions to Accelerate Scientific Innovation
Certara, Inc. recently announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software that allows life sciences organizations to perform predictions and answer…
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for the Treatment of PCED
Kala Pharmaceuticals, Inc. recently announced the US FDA has accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human…
Gilead to Acquire All Remaining Rights to Potential First-In-Class Immunotherapy
Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under….
Minerva Neurosciences Announces Update on its NDA for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences, Inc. recently announced that following the Type A meeting held on November 30, 2022, the US FDA has confirmed the refuse to file…
Eyenovia Aims to Revolutionize Ophthalmology Devices With Microdose Array Print (MAP) Technology
While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard eye dropper used today has gone largely unchanged….
Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate
Valneva SE recently announced it has completed rolling submission of the Biologics License Application (BLA) to the US FDA for its single-shot chikungunya vaccine candidate, VLA1553.…
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
DBV Technologies recently announced that the US FDA has lifted the partial clinical hold on the Company’s VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety,…
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia
KemPharm, Inc. recently announced the initiation of a Phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep…
Jazz Pharmaceuticals & Zymeworks Announce Jazz has Confirmed Opt-In & Advances Partnership
Jazz Pharmaceuticals plc and Zymeworks Inc. recently announced Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks’ zanidatamab in key markets….
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
Achieve Life Sciences, Inc. recently announced the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,459,328 covering the mesylate salt formulation…
atai Life Sciences Initiates Phase 2b Proof-of-Concept Trial of RL-007 for Cognitive Impairment Associated With Schizophrenia
The Phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS)…..
Carrick Therapeutics & The Menarini Group Announce Clinical Trial Collaboration
Carrick Therapeutics and the Menarini Group recently announced a clinical trial collaboration and supply agreement that covers the execution of a Phase 2 clinical trial to evaluate the novel combination of….
